Rituximab-treated rheumatoid arthritis patients were shown to have impaired expansion of influenza virus–specific CD8+ T cells following influenza vaccination, a finding also seen in B cell–deficient mice challenged with influenza virus (62). Here, CD8A is linked to rheumatoid arthritis.